Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. Show More...

  • Website http://www.chugai-pharm.co.jp
  • Sector Healthcare
  • Industry Drug Manufacturers-General
  • Last Quote 45.67 EUR
  • Last Updated 29-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share JPY 76.12 64.73 84.58 93.35 93.38 111.79 97.97 132.83 168.8 287.43 317.51
    Dividends JPY 23.0 40.0 40.0 45.0 48.0 52.0 52.0 62.0 72.0 96.0 96.0
    Payout Ratio % * 57.8 57.4 41.1 46.8 48.2 50.2 44.5 40.8 35.0 30.2
    Shares Mil 544.0 544.0 544.0 545.0 546.0 547.0 547.0 547.0 548.0 548.0 548.0
    Book Value Per Share * EUR 7.42 8.23 7.49 6.98 7.28 8.53 9.39 9.14 10.66 12.14 13.21
    Free Cash Flow Per Share * EUR 0.58 1.44 0.84 0.74 0.25 0.68 0.07 0.29 1.32 1.24
    Return on Assets % 7.9 6.77 8.6 7.92 7.1 8.01 6.73 8.77 10.44 15.93 17.6
    Financial Leverage (Average) 1.13 1.17 1.2 1.22 1.24 1.26 1.25 1.23 1.22 1.24 1.22
    Return on Equity % 9.41 7.78 10.18 9.6 8.73 10.0 8.43 10.87 12.78 19.57 21.56
    Return on Invested Capital % 9.36 7.73 10.13 9.6 8.73 10.0 8.43 10.88 12.78 19.59 21.57
    Interest Coverage 866.67 883.1
    Current Ratio 7.08 6.09 5.19 5.16 4.71 4.27 4.68 4.87 4.43 3.9 3.97
    Quick Ratio 4.57 4.05 3.62 3.71 3.41 2.97 3.02 3.39 3.17 2.87 2.8
    Debt/Equity